Join

Compare · CBOE vs CNCR

CBOE vs CNCR

Side-by-side comparison of Cboe Global Markets, Inc. (CBOE) and Loncar Cancer Immunotherapy ETF (CNCR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CBOE and CNCR operate in n/a (n/a), so they compete in similar markets.
  • CBOE carries a market cap of $13.01B.
  • CBOE has hit the wire 21 times in the past 4 weeks while CNCR has been quiet.
  • CBOE has more recent analyst coverage (25 ratings vs 0 for CNCR).
MetricCBOECNCR
Company
Cboe Global Markets, Inc.
Loncar Cancer Immunotherapy ETF
Price
$280.07-0.42%
$9.16+2.35%
Market cap
$13.01B
-
1M return
-17.29%
-
1Y return
+27.78%
-
Sector
n/a
n/a
Industry
n/a
n/a
Exchange
NASDAQ
NASDAQ
IPO
2010
n/a
News (4w)
21
0
Recent ratings
25
0
CBOE

Cboe Global Markets, Inc.

Cboe Global Markets, Inc., through its subsidiaries, operates as an options exchange worldwide. It operates through five segments: Options, North American Equities, Futures, European Equities, and Global FX. The Options segment trades in listed market indices. The North American Equities segment trades in listed U.S. and Canadian equities; and offers exchange-traded products (ETP) transaction and ETP listing services. The Futures segment trades in futures. The European Equities segment offers pan-European listed equities transaction services, ETPs, exchange-traded commodities, and international depository receipts, as well as ETP listings and clearing services. The Global FX segment provides institutional foreign exchange (FX) trading and non-deliverable forward FX transactions services. The company has strategic relationships with S&P Dow Jones Indices, LLC; FTSE International Limited; Frank Russell Company; MSCI Inc.; and DJI Opco, LLC. The company was formerly known as CBOE Holdings, Inc. and changed its name to Cboe Global Markets, Inc. in October 2017. Cboe Global Markets, Inc. was founded in 1973 and is headquartered in Chicago, Illinois.

CNCR

Loncar Cancer Immunotherapy ETF

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.